MIAMI, FL -- (MARKET WIRE) -- April 04, 2007 -- DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or “The Company”) announced that it plans to initiate a clinical development program in humans with its Lipid Polymer Micelle (“LPM™") oral drug delivery technology. The LPM™ system is a platform technology designed to allow for the oral administration of drugs such as leuprolide that are water-soluble but poorly permeable through the gastrointestinal tract. DOR has previously demonstrated in preclinical animal models that the LPM™ technology is adaptable to oral delivery of peptide drugs and that high systemic levels after intestinal absorption can be achieved with the peptide hormone drug leuprolide.
